Shlomi Raz, Eleusis CEO
June 10, 2022 09:21 AM EDTUpdated 11:16 AM
Financing
Deals

Psy­che­delics start­up Eleu­sis ax­es SPAC deal, but CEO con­fi­dent its IV psilo­cy­bin ther­a­py will en­ter clin­ic next month

Kyle LaHucik

Senior Reporter

Just two days af­ter re­ceiv­ing ap­proval from the UK’s drug reg­u­la­tor to start a Phase I tri­al, Eleu­sis and blank check part­ner Sil­ver Spike can­celed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times